Spanagel R, Putzke J, Stefferl A, Schöbitz B, Zieglgänsberger W
Max Planck Institute of Psychiatry, Department of Neuroendocrinology, Munich, Germany.
Eur J Pharmacol. 1996 Jun 3;305(1-3):45-50. doi: 10.1016/0014-2999(96)00175-6.
The suppressing effect of acamprosate (calcium-acetyl homotaurinate) on alcohol drinking is well established; however, little is known about its effects upon the alcohol-induced withdrawal syndrome. Male Wistar rats received as a sole drinking fluid a 20% (v/v) alcohol solution for one week. Animals consumed on average 5.3 +/- 0.3 g/kg per day alcohol, which resulted in blood alcohol levels of 38 +/- 14 mg/dl. For the quantification of alcohol withdrawal we used a new radio-telemetric system which enabled us to monitor body temperature, locomotor activity, food and water intake patterns constantly during alcohol withdrawal. Although alcohol intake and the resulting blood alcohol levels were low, clear signs of withdrawal could be observed. Thus, hyperthermia and hyperlocomotion occurred 18 h after the termination of forced alcohol drinking. Food intake was initially enhanced but dropped significantly below basal food intake in control animals one day after the termination of forced alcohol drinking. Acamprosate given twice a day (200 mg/kg, i.p., 8 a.m. and 8 p.m.) reduced hyperlocomotion and food intake significantly in the alcohol withdrawal animals, however, it did not change withdrawal-induced hyperthermia. When acamprosate was given to alcohol-naive animals, it increased locomotor activity and body temperature transiently, in particular during the rats' active night phase. In summary, (i) the radio-telemetric system used in the present study proved to be a very sensitive method for quantifying alcohol-induced withdrawal symptoms; (ii) acamprosate reduced alcohol-induced physical signs of withdrawal, however, this effect could not be observed for all parameters measured, which might be explained by the fact that (iii) acamprosate exerts a slight, transient psychomotor stimulant effects by itself.
阿坎酸(钙-乙酰高牛磺酸钙)对饮酒的抑制作用已得到充分证实;然而,关于其对酒精诱导的戒断综合征的影响却知之甚少。雄性Wistar大鼠以20%(v/v)酒精溶液作为唯一的饮用水,持续一周。动物平均每天摄入5.3±0.3 g/kg酒精,导致血液酒精水平达到38±14 mg/dl。为了量化酒精戒断,我们使用了一种新的无线电遥测系统,该系统使我们能够在酒精戒断期间持续监测体温、运动活动、食物和水的摄入模式。尽管酒精摄入量和由此产生的血液酒精水平较低,但仍可观察到明显的戒断迹象。因此,在强制饮酒结束后18小时出现体温过高和运动亢进。食物摄入量最初增加,但在强制饮酒结束一天后,明显低于对照动物的基础食物摄入量。每天两次给予阿坎酸(200 mg/kg,腹腔注射,上午8点和晚上8点)可显著降低酒精戒断动物的运动亢进和食物摄入量,然而,它并未改变戒断引起的体温过高。当给未接触过酒精的动物服用阿坎酸时,它会短暂增加运动活动和体温,特别是在大鼠活跃的夜间阶段。总之,(i)本研究中使用的无线电遥测系统被证明是一种非常敏感的量化酒精诱导戒断症状的方法;(ii)阿坎酸减少了酒精诱导的身体戒断体征,然而,并非所有测量参数都能观察到这种效果,这可能是因为(iii)阿坎酸本身会产生轻微的、短暂的精神运动兴奋作用。